Iv Therapy Articles & Analysis
14 news found
SeValent is designed to enable intravenous (IV)-only therapies to now be delivered subcutaneously in a controlled manner for use in the home setting. ...
Bexson’s Chief Executive Officer, Gregg Peterson, and Chief Scientific Officer, Jeffrey Becker, are scheduled to present on Thursday, September 22nd, 2022 in New York City, NY and will discuss various new and innovative therapies for the treatment of mental health. Management will be participating in investor one-on-one meetings while in attendance. ...
The first part of the clinical trial will evaluate increasing doses of the NK1R+ MSCs and the optimal dose will be taken to Phase II in a randomized study in adult patients recovering from ARDS due to COVID-19. "This investigational cell therapy is administered intravenously (IV) and follows a significant body of compelling clinical results by NIH investigators ...
The Ventura Shunt is currently being evaluated in an international, multicenter RELIEVE-HF randomized trial in patients with both reduced and preserved ejection fraction who are advanced NYHA Class II, Class III and ambulatory Class IV and on guideline directed medical therapies. The financing was led by Deerfield Management with participation from Aperture ...
In the EU it is indicated for symptomatic chronic HF in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy. “Vericiguat is currently approved in several countries for heart failure patients who have recently experienced a worsening event. ...
ByBayer AG
Single IV cycle of PsiOxus’ T-SIGn vector enabled an otherwise non-effective dose of CAR-T cell therapy to clear primary and metastatic tumors in vivo Reprogramming of the tumor microenvironment using T-SIGn vectors could enable a variety of CAR-T therapies to overcome limitations in solid tumors Data is currently being presented at the ...
The Ventura Interatrial Shunt is currently being evaluated in the international, multicenter RELIEVE-HF randomized trial in patients with both reduced and preserved ejection fraction who are advanced NYHA Class II, Class III and ambulatory Class IV and already receiving optimal medical therapies. The company is also conducting the RELIEVE-PAH trial from patients ...
The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies”. ...
This includes data from three phase III studies, ACLIFORM, AUGMENT and AMPLIFY, and the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations. ...
Patients who are ineligible for intravenous tissue plasminogen activator (IV t-PA) or who fail IV t-PA therapy are candidates for treatment. See Instructions for Use for complete indications, contraindications, warnings, precautions, and adverse events. ...
The label also includes clinical data from the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations. ...
The label also includes clinical data from the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations. ...
Stem Cell Inc, a leader in regenerative medicine products and services, today announced its three partially owned Florida-based clinics have expanded their menu of services to help meet the growing market demand and patient needs for regenerative therapies. In addition to continuing to offer targeted stem cell therapies of all kinds — bone marrow, adipose, ...
Braun Medical Inc., a leader in infusion therapy and pain management. Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. ...